Back to search results

Early Restart of RAS Inhibitors After Acute Kidney Injury

This study is looking at whether it's safe and practical to restart certain blood pressure medications, called Renin-Angiotensin System Inhibitors (RASi), sooner after a patient has acute kidney injury (AKI). Researchers will compare an "early RASi restart strategy" to "usual care" where doctors decide when to restart the medication. You may be able to join if you are 18 or older, were taking RASi before your hospital stay for conditions like heart failure or kidney disease, and your RASi was stopped due to AKI. The main goal is to see if restarting RASi early is feasible. The study is currently unclear on its recruitment status.

Study design
This is a pilot interventional study with 60 participants. It compares two groups: one receiving an early RASi restart and another receiving usual care.
What's involved
If you join, you will restart RASi according to the study plan, have a lab test 1-2 weeks after restarting if not part of routine care, and answer questions at a 90-day follow-up.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed up to 90 days after enrollment or hospital discharge.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07734636

A Prompt REstart Study of Renin-Angiotensin System Inhibitors After Acute Kidney Injury

Not Yet Recruiting
PHASE4Ages 18+InterventionalTreatment
University of California, San Francisco
~60 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:Early RASi restart strategyUsual Care

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility- RASi use separation
Measured over From date of enrollment until date of hospital discharge or up to 90 days if remains in the hospital

Conditions

Acute Kidney Injury

Explore related trials

Acute Renal Failure

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Yuenting D Kwong, MD MAS · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

Yuenting D Kwong, MD MAS
[email protected]
415-514-7371
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Pre-admission RASi use for Class I indication (e.g., heart failure, kidney disease)
RASi stopped in the setting of AKI (defined by ≥1.5x baseline SCr)
AKI in recovery (defined by a decrease in SCr by ≥0.3mg/dL from peak)

Exclusion

RASi allergy or contraindication (i.e., angioedema, bilateral renal artery stenosis)
Ongoing dialysis requirement
Pregnant or breastfeeding
Prisoner
Palliative or hospice care involvement
Unable to consent
No enteral route of medication administration
Clinician judgment

What this trial measures

  • Feasibility- RASi use separationFrom date of enrollment until date of hospital discharge or up to 90 days if remains in the hospital

    Proportion of patients in the early RASi restart arm and the usual care arm who restart RASi within 72 hours of SCr downtrending by ≥0.3mg/dL from peak SCr and at hospital discharge